Top Markets
Coin of the day
PT Itama Ranoraya Tbk PT Itama Ranoraya Tbk

PT Itama Ranoraya Tbk

IRRA
Clasificación en acciones #27332
PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical... PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia. The company offers in vitro diagnostics products comprising rapid test and clinical laboratory; medical imaging products, including bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; cardiovascular, urology, and surgical products; and hospital supplies. It also provides cold chain management, such as cold room, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products. In addition, the company leases office space. It sells its products under the oneject, Abbott, Terumo, Medtronic, HMD, BD, Vestfrost, Hemocue, Planmed, Sinmed, Balmed, Zepa, KSM CARE, Trisan Care, GEA, Hologic, IS, Avimac, RadmediX, MTS, and SMAM brands. PT Itama Ranoraya Tbk was founded in 1988 and is based in Jakarta Timur, Indonesia. PT Itama Ranoraya Tbk is a subsidiary of PT Global Dinamika Kencana.
Precio por acción
$0.02222751
Capitalización bursátil
$33.52M
Cambio (1 día)
0.54%
Cambio (1 año)
-16.22%
País
ID
Comercio PT Itama Ranoraya Tbk (IRRA)

Categoría

Ganancias de PT Itama Ranoraya Tbk (IRRA)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di PT Itama Ranoraya Tbk, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de PT Itama Ranoraya Tbk desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$6.46B -
US
- -
US
$2.17B -
US
- -
US
$358.16M -
AU